Salute e Benessere
Facial Injectables Market Poised to Reach US$ 37.1 Billion by 2031, Driven by Growing Demand for Non-Invasive Procedures and Technological Innovations | TMR
Facial injectables are commonly used on nasolabial folds, cheekbones, and lips. For instance, dynamic wrinkles caused by different movements are minimized by injecting botulinum toxin, often known as Botox, into the face's muscles.
Rise in popularity of social media is a key factor fostering market expansion. A large percentage of the population that opts for cosmetic procedures that involve facial injectables consults an online source.
This tech savvy population, primarily the younger generation, is often exposed to information regarding such procedures on platforms such as Instagram and Facebook. Additionally, celebrity influencers are driving market progress.
Dermal fillers often consist of hyaluronic acid, polylactic acid, or calcium hydroxylapatite; Botox is a neurotoxic protein. These treatments, which are administered by medical professionals, provide immediate results that usually last a few months to a year.
Growth in the elderly population and increase in popularity of cosmetic operations among the aging people are likely to propel the expansion of the facial injectables landscape.
A recent WHO report stated that one in six people in the world will be aged 60 years or above by 2030. The global population of people aged 60 years and older will double (2.1 billion) by 2050. The number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million.
Prominent companies in the global facial injectables market are striving to create sophisticated fillers with enhanced characteristics.
In order to meet the needs and preferences of individual patients, they are introducing injectables with improved qualities, such as improved safety profiles, greater integration with tissues, and longer-lasting benefits.
In July 2024 , the U.S. FDA approved a new indication for the anti-wrinkle injectable, which was first introduced in 2011 to treat moderate to severe wrinkles between the glabellar lines. This expansion makes the neurotoxin the only one that can simultaneously treat crow's feet and the upper forehead lines.
North America was the leading contributor to the market share in 2022. The region is expected to maintain its dominance during the forecast period.
Growth in number of people opting for esthetic procedures to enhance physical appearances, surge in technological advancements, presence of well-established healthcare facilities, and significant presence of advanced medical spas and cosmetic surgery centers are propelling market development in the region.
According to the , cosmetic surgery procedures rose by 19.0% in 2022 as compared to that in 2019. Procedures related on the body, including liposuction, tummy tuck (abdominoplasty), and arm and lower body lifts dominated, with a 25% rise and 576,485 procedures in total in 2022.
Allergan, Inc., Ipsen (Mayroy SA), Merz Pharma, Suneva Medical, Inc., Medytox, Inc., Sinclair Pharma, Bloomage BioTechnology, Anika Therapeutics, Inc., Prollenium Medical Technologies, and Galderma are the prominent companies functioning in the global facial injectables landscape.
Prominent players are collaborating with numerous biotech companies, research institutes, and esthetics companies in order to develop cutting-edge injectables.
They are also collaborating strategically with cosmetic surgeons and dermatologists to improve clinical acceptance and develop products based on expert input. Such partnerships are likely to ensure the highest levels of efficacy and safety.
a performance beauty company that focuses on developing an esthetic portfolio, announced that it had signed a definitive agreement with Symatese to serve as the exclusive distributor for four distinct dermal fillers in late-stage development in the U.K. and Europe .
The fillers are expected to receive regulatory clearances in the second half of 2024 and go on sale under the brand name ESTYME Fillers in 2025.
This is the second deal Symatese and the company had reached; the first granted exclusive distribution rights to the same product line in the U.S, where it will be marketed in 2025 under the Evolysse brand.
Transparency Market Research, a global registered at Wilmington, Delaware , United States , provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
+1-518-618-1030
866-552-3453
Logo: https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/facial-injectables-market-poised-to-reach-us-37-1-billion-by-2031--driven-by-growing-demand-for-non-invasive-procedures-and-technological-innovations--tmr-302213431.html